U.S., May 6 -- ClinicalTrials.gov registry received information related to the study (NCT07567690) titled 'Real-world Immunogenicity of Anti-IL5/5a Antibody' on April 22.
Brief Summary: This study aims to evaluate the immunogenicity of the drug by measuring anti-drug antibody (ADA) formation and titers. The presence of ADAs will be assesses to determine their potential impact on the drug's efficacy and safety.
Study Start Date: Aug. 19, 2025
Study Type: OBSERVATIONAL
Condition:
Asthma
Immunogenicity
Biologics
Recruitment Status: ACTIVE_NOT_RECRUITING
Sponsor: Samsung Medical Center
Information provided by (Responsible Party): Noeul KANG, Samsung Medical Center
Published by HT Digital Content Services with permission from Health Dai...